// App-Quantinova.ai

371 : A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.

Researchers

Presenter

  • Teresa Macarulla

Principal Investigators

  • Josep Tabernero

  • Daniel H. Palmer

  • Sunil Sharma

  • Kenneth H. Yu

  • Dalila B. Sellami

  • Jocelyn Zhou

  • Wu Yi

  • Hildegard Boss

  • Eunice L Kwak

Medical Centers

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • University of Liverpool Cancer Research UK Centre, Liverpool, United Kingdom

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Massachusetts General Hospital, Boston, MA

Locations

  • Spain

  • United Kingdom

  • United States

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Sonidegib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01487785

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved